Strong Collaboration is Essential for Radiation Oncologists and Other Experts

News
Video

As a radiation oncologist, James B. Yu, MD, MHS, FASTRO, works with urologists, medical oncologists, radiologists, pathologists, physicists, and health services researchers.

As an expert in genitourinary cancers, he spoke about working with urologists as they are often the main “proceduralists” for diagnosing cancer, and medical oncologists as they would be the next step for the patient, after radiation fails them. When it comes to research, as Yu has a specific interest in that aspect of work, he collaborates with radiologists, pathologists, physicists, and health services researchers. All of this comes along with working with patients.

As Yu, professor in the Department of Radiation Oncology and Applied Sciences, leader of the Genitourinary Radiation Oncology Program at Dartmouth Hitchcock Medical Center, and radiation oncology editorial advisory board member of the Journal ONCOLOGY®, stated, “radiation oncologists are at the end of the referral stream, so if you can’t collaborate with people or respond to referring physicians, then you’re not going to do very well in radiation oncology.”

Transcript:

Radiation oncologists are at the end of the referral stream, so if you can’t collaborate with people or respond to referring physicians, then you’re not going to do very well in radiation oncology. In genitourinary radiation oncology, the urologists are the ones who are the main proceduralists. They refer patients [to us], they do the diagnosis, and [they] collaborate [with us] in academic research. Medical oncologists are critical if radiation fails or if you want to do novel combination therapies, and they also have internal medicine training, which the vast majority of us don’t. Those 2 groups are critical to any genitourinary radiation oncology practice.

Then, in research, having good radiologists and pathologists facilitates your research tremendously. Physicists, as well, are a huge part of radiation oncology—they’re often the ones thinking of the most novel technical innovations. In the work that I do in research, health outcomes and health services researchers and people in public health [are important]—my mentor in research is an internal medicine physician who has an interest in cancer. The more people you can work with outside of radiation oncology, the more interesting your world is going to be, and the more fulfilling [it will be].

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.
Related Content